Peytour Yann, Villacreces Arnaud, Chevaleyre Jean, Ivanovic Zoran, Praloran Vincent
Univ. Bordeaux, CIRID, UMR 5164, F-33000 Bordeaux, France.
Stem Cell Res. 2013 Sep;11(2):736-42. doi: 10.1016/j.scr.2013.05.001. Epub 2013 May 11.
New adult stem cell sources, devoid of the technical/ethical/economical barriers of those presently available, would favor the ongoing development of in vitro cell engineering and transplantation. Hematopoietic transplantation opened the way to and remains the most successful cell transplantation procedure. CD34+ cells that include hematopoietic stem cells (HSCs) and hematopoietic progenitors (HPs) are presently harvested from bone marrow (BM), cord blood or peripheral blood (after being mobilized from BM). The panel of potential donors, the quantities of collected cells and some other technical/medical problems still represent limiting factors to their transplantation in some patients. Steady state peripheral blood (SSPB) contains very low frequencies of CD34+ cells. They are trapped in leukoreduction filters (LRFs), which are discarded after the preparation of therapeutic red blood cell concentrates from individual blood donations. We recently developed a procedure allowing the easy and rapid elution of CD34+ cells from LRFs and we showed that they are functionally similar to those harvested from other sources. After providing an overview of the sources, interests and limitations of therapeutic HSCs presently available, we will provide arguments based on our and others' results suggesting that SSPB could become an attractive source of HSCs for hematopoietic transplantation and of other cell types for various research/development procedures.
新型成人干细胞来源不存在目前可用来源的技术/伦理/经济障碍,将有利于体外细胞工程和移植的持续发展。造血移植开辟了道路,并且仍然是最成功的细胞移植程序。目前,包含造血干细胞(HSCs)和造血祖细胞(HPs)的CD34+细胞是从骨髓(BM)、脐带血或外周血(从骨髓动员后)中采集的。潜在供体群体、采集细胞的数量以及其他一些技术/医学问题在某些患者的移植中仍然是限制因素。稳态外周血(SSPB)中CD34+细胞的频率非常低。它们被困在白细胞滤除器(LRFs)中,在从个体献血制备治疗性红细胞浓缩物后,这些滤器会被丢弃。我们最近开发了一种程序,可以轻松快速地从LRFs中洗脱CD34+细胞,并且我们表明它们在功能上与从其他来源采集的细胞相似。在概述了目前可用的治疗性造血干细胞的来源、优势和局限性之后,我们将基于我们自己和其他人的研究结果提出论据,表明SSPB可能成为造血移植中造血干细胞以及各种研究/开发程序中其他细胞类型的有吸引力的来源。